Category: Tandem Diabetes Care Inc.
Tandem Diabetes Care says it's planning a 5.25-million-share offering worth $60 million for its line of insulin pumps.
Tandem Diabetes Care (NSDQ:TNDM) said last week that it's planning a $60 million public offering for its line of insulin pumps.
Tandem Diabetes shares gain today after the FDA grants 510(k) clearance for the Tandem's t:flex insulin pump, which has a larger reservoir than its t:slim predecessor.
Tandem Diabetes teams with a non-profit to boost access to a diabetes data through an open-source software platform.
Tandem Diabetes' shares lose about 7% in morning trading after the company widens its insulin cartridge recall to include older units.
Tandem Diabetes recalls more than 4,700 boxes of insulin cartridges designed for use with its t:slim insulin pump over concerns that the cartridges may leak and result in over- or under-doses of insulin.
Tandem Diabetes Care says it sold all 9.2 million shares offered in its initial public offering at $15 per share, raising $138 million.
Tandem Diabetes Care (NSDQ:TNDM) closed its initial public offering yesterday after selling all 9.2 million shares on offer for $15 apiece, raising $138 million.
The underwriters of Tandem Diabetes Care's initial public offering exercise an over-allotment of 1.2 million shares, adding $18 million to the IPO.
Tandem Diabetes Care (NSDQ:TNDM) said today that the underwrites of its initial public offering picked up a 1.2 million-share over-allotment at $15 per share, adding $18 million to the IPO's value.